PeptiDream Inc. (TYO:4587)
1,090.00
-32.00 (-2.85%)
Nov 18, 2026, 10:40 AM JST
PeptiDream Revenue
PeptiDream had revenue of 5.59B JPY in the quarter ending September 30, 2026, with 29.67% growth. This brings the company's total for the last twelve months to 20.48B, up 14.25% year-over-year. In the year 2025, PeptiDream had annual revenue of 18.52B, down -60.32%. That makes PeptiDream the 20,854th largest company in the world by revenue and 2,259th in Japan.
Revenue (ttm)
20.48B
Revenue Growth
+14.25%
P/S Ratio
7.00
Revenue / Employee
26.74M
Employees
766
Market Cap
140.14B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full PeptiDream breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.52B | -28.16B | -60.32% |
| Dec 31, 2024 | 46.68B | 17.96B | 62.57% |
| Dec 31, 2023 | 28.71B | 1.86B | 6.93% |
| Dec 31, 2022 | 26.85B | 17.49B | 186.70% |
| Dec 31, 2021 | 9.37B | -2.31B | -19.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GNI Group | 37.21B |
| Nxera Pharma | 35.51B |
| 3-D Matrix | 11.92B |
| RaQualia Pharma | 3.90B |
| Heartseed | 3.03B |
| Japan Tissue Engineering | 2.68B |
| Cuorips | 128.00M |
| Healios K.K. | 47.00M |
PeptiDream News
- 6 days ago - PeptiDream Quarterly report: Q3 2026 - Filings
- 3 months ago - PeptiDream Earnings Call Transcript: Q2 2026 - Transcripts
- 3 months ago - PeptiDream Quarterly report: Q2 2026 - Filings
- 3 months ago - PeptiDream Slides: Q2 2026 - Filings
- 4 months ago - PeptiDream appoints three new executive vice presidents - TheFly
- 5 months ago - PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer - Business Wire
- 5 months ago - PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - Business Wire
- 5 months ago - Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewsWire